Ulcerative Colitis – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in both mature (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) and emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South Korea, and Turkey), as well as countries from the Americas, Asia-Pacific, Europe, Middle East, and Africa. We report the diagnosed prevalence of UC for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s UC forecast will answer the following questions:

  • Of all people with UC, how many in each country have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of UC over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following UC subpopulations:

  • Incident cases by diagnosis status.
  • Diagnosed prevalent cases by extent of disease.
  • Diagnosed prevalent cases by treatment scheme (for high-income countries).
  • Burden of illness

Note: Coverage may vary by country.

launch Related Market Assessment Reports